Replies to post #753377 on NorthWest Biotherapeutics Inc (NWBO)

[antihama]

Regarding your #3, I get a different take than you. Per NWBOs PR

The primary endpoint for each of the 2 pediatric trials will be overall survival, determined by comparing the survival of DCVax-L treated patients to matched contemporaneous external controls. The external controls will be identified using the same methodology as was used to pre-specify the external controls in the Statistical Analysis Plan for the Company’s Phase III trial in adult patients.